Where Zimmer Biomet Holdings Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have evaluated Zimmer Biomet Holdings (NYSE:ZBH), with a mix of bullish, bearish, and neutral ratings. The average 12-month price target has decreased slightly to $134.25. Recent analyst actions include both downgrades and upgrades, reflecting varied sentiments about the company's future performance.
July 01, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zimmer Biomet Holdings has received mixed analyst ratings over the past three months, with a slight decrease in the average 12-month price target to $134.25. Recent analyst actions include downgrades from Piper Sandler and Barclays, and upgrades from Oppenheimer and Evercore ISI Group.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Zimmer Biomet Holdings' stock price. The varied sentiments from different analysts indicate uncertainty about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100